Following an application by the National Institute of Agricultural Sciences (NIAS), a risk assessment study group under MAFF cleared the use of HC-EGFP Bombyx mori recombinant silkworms. There may be future interest to explore the use of recombinant silkworms for the production of veterinary drugs.
Nikkei Biotech news releases, January 31 and February 3
MAFF review meeting agrees to Cartagena protocol safety status of transgenic silkworm variant